APM Stock Price – Aptorum Group Ltd soars 290% then collapses after venturing into infectious diseases


  • NASDAQ: APM ended Tuesday's session with a surge of 90% after hitting even higher levels.
  • Shares then collapsed back below $3, completing a pump-and-dump move. 
  • Aptorum Group launched a new unit focused on an infectious disease liquid biopsy unit.
  • Venturing into a new field involving the coronavirus implies strong growth for the low-valued company.

When a stock trades at rock-bottom levels, a small spark is all that is needed to trigger a surge. Aptorum Group Ltd nearly quadrupled in value in Tuesday's intense session, closing at $4.76 after already hitting a high of $14.23. Shares then collapsed back below $3 on a Wednesday session dominated by bears, taking the price back nearly to Monday's levels. On Thursday, trading action was quiet, with NASDAQ:APM closing at $2.89 after staying the whole session between $2.7 and $3.1.

APM stock price chart

After the recent leap and plunge, NASDAQ: APM's market capitalization is only $87.82 million. Can it rise?

APM Stock News

Aptorum jumped after announcing the launch of Aptorum Innovations, a subsidiary focused on infectious disease liquid biopsy diagnostics. When speaking of diseases that spread rapidly, SARS-Cov-2 – the virus behind COVID-19 – immediately comes to mind.

Indeed, Aptorum has in-licensed exclusive rights to develop novel molecular-based rapid pathogen identification and detection diagnostics (RPIDD) technology with a Singapore-based company called Accelerate Technologies PTE Ltd. The fir is the commercialization arm of the city-state's Agency for Science, Technology, and Research. 

The collaboration with a firm backed by Singapore – a country that successfully battled the coronavirus, is inspiring investors.

While several COVID-19 vaccines are at a late stage, there is still room for those specializing in rapid identification of this coronavirus and potentially new ones that could appear in recent years. It is essential to note that the full mitigation of the original SARS disease from 2002-2003 was never fully achieved. 

Broader markets are focused on the chaotic presidential debate – which veered away from the virus – yet its prominence is still critical for investors. 

See Presidential Debate: Stocks set to suffer on Trump's refusal to accept the results

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Recommended content


Recommended content

Editors’ Picks

EUR/USD slides to 1.0650 amid strong USD, dovish ECB commentary

EUR/USD slides to 1.0650 amid strong USD, dovish ECB commentary

EUR/USD is falling further to test 1.0650 after dovish commentary from the ECB policymaker Stournaras weighed on the Euro. Divergent ECB-Fed policy outlooks keep the US Dollar strongly bid ahead of the US sentiment data and Fedspeak. 

EUR/USD News

GBP/USD extends decline below 1.2500 on sustained USD strength

GBP/USD extends decline below 1.2500 on sustained USD strength

GBP/USD extends losses below 1.2500, struggling even after the January month UK GDP was revised higher to 0.3% while the UK industrial sector showed robust growth. Resurgent US Dollar demand and geopolitical tensions keep the pair undermined. 

GBP/USD News

Gold price taps on $2,400 for the first time on record

Gold price taps on $2,400 for the first time on record

Gold price tests $2,400 for the first time on record, scaling new lifetime highs amid persistent geopolitical tensions. The upsurge seems unaffected by reduced Fed rate cut bets and bullish USD. Extremely overbought conditions might prompt some profit-taking around the metal.

 

Gold News

Robert Kiyosaki steers clear from ETFs, opts for holding Bitcoin directly instead

Robert Kiyosaki steers clear from ETFs, opts for holding Bitcoin directly instead

Rich Dad Poor Dad author Robert Kiyosaki says he will not buy Bitcoin ETFs. Kiyosaki stated his dislike for Wall Street’s financial products and preferred packaging his own. 

Read more

US banks in focus, as earnings season gets underway

US banks in focus, as earnings season gets underway

Today sees the big banks kick off earnings season in the US, with JP Morgan Chase, Wells Fargo, Blackrock, Citigroup, and State Street all reporting before the bell.

Read more

Forex MAJORS

Cryptocurrencies

Signatures